



IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 4727-C2-03-DCL	
In Re Application Of: Michael Rubin, et al.					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/719,554	11/21/2003	Not yet assigned	29668	Not assigned	3555
Title: Oral Compositions Containing Nsaids and Essential Oils					
<p>Address to:</p> <p>Commissioner for Patents</p> <p>P.O. Box 1450</p> <p>Alexandria, VA 22313-1450</p>					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 4727-C2-03-DCL	
In Re Application: Michael Rubin, et al.						
Application No.	Filing Date	Examiner	Prior Art No.	Group Art Unit	Confirmation No.	
10/719,554	11/21/2003	Not yet assigned	29668	Not assigned	3555	
Oral Compositions Containing Nsaids and Essential Oils						
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
<input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 23-0458 as described below. <input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input type="checkbox"/> Charge any additional fee required.						
Certificate of Transmission by Facsimile*			Certificate of Mailing by First Class Mail			
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)			I certify that this document and fee is being deposited on 7/15/04 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
_____ (Date)			 _____ Signature of Person Mailing Correspondence			
_____ Signature			Lisa Peters _____ Typed or Printed Name of Person Mailing Certificate			
_____ Typed or Printed Name of Person Signing Certificate						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*This certificate may only be used if paying by deposit account.</p>  _____ Signature </div> <div style="width: 45%; text-align: right;"> <p>Dated: July 15, 2004</p> </div> </div>						
Darryl C. Little, Reg. No.: 40,703 Warner-Lambert Company LLC 201 Tabor Road Morris Plains, NJ 07950 Phone: 973-385-4401 FAX: 973-385-3117						
CC:						



Docket No.: 4727-C2-03-DCL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Michael Rubin et al.

Serial No.: 10/719,554

Group Art Unit: Not Yet Assigned

Filed: 11/21/2003

Examiner: Not Yet Assigned

For: Oral Composition Containing Nsaids and Essential Oils

Customer No.: 29668

Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449 submitted in accordance with 37 C.F.R §1.98 (a) (1) and 1.98 (b). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein.

While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. § 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R SECTION 1.8

I hereby certify that this correspondence and any documents referred to as enclosed are being deposited, pursuant to 37 C.F.R. Section 1.8, with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents, Alexandria, VA 22313-1450 on this 15th day of July, 2004.

By: Lisa Peters
Lisa Peters



Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney or agent of record believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. § 1.98 (a) (2), unless otherwise indicated herein, a copy of each of the listed references or relevant portion thereof is also enclosed.

In accordance with 37 C.F.R. § 1.98(c), all English translations within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) of each non-English reference, if any, are also enclosed.

The following are also included, if applicable, and as required under 37 C.F.R. § 1.98:

- ☐ In accordance with 37 C.F.R. § 1.98 (a) (3), the following concise explanation of the relevance of each listed reference that is not in the English language and is not accompanied by a translation into English or discussed in the present specification, is provided.
- ☐ The following listed references are not enclosed because, under 37 C.F.R. § 1.98 (c), they are substantially cumulative of the _____ reference:
- ☒ The following listed references are not enclosed because, under 37 C.F.R. § 1.98 (d), they were previously cited by or submitted to the Office in prior application **U.S. 09/761,026 which was filed 01/16/2001**, which is relied upon for an earlier filing date under 35 U.S.C. 120.

The certification specified in 37 C.F.R. § 1.97 (e), if required, is made below:

- ☐ I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (1).
- ☐ I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (2).



Please credit any overpayment or charge any additional fees to Deposit Account
No.: 23-0458.

Date:

7/15/04

Respectfully submitted,

Darryl C. Little
Reg. No. 40,703
Attorney For Applicant

Warner-Lambert Company LLC
201 Tabor Road
Morris Plains, NJ 07950
Phone: (973) 385-4401
FAX: (973) 385-3117

Sheet 1 of 1

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 4727-C2-03-DCL	SERIAL NO. 10/719,554
	APPLICANT Michael Rubin et al.	
	FILING DATE 11/21/2003	GROUP Not Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 4 0 5 6 0 4	4/11/95	Hall			
	5 4 4 7 7 2 5	9/5/95	Damani et al.			
	5 3 6 4 6 1 6	11/15/94	Singer et al.			
	4 9 3 3 1 7 2	6/12/90	Clark, Jr. et al.			
	5 4 7 2 6 8 4	23/5/95	Nabi et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
WO	9 7 2 0 5 7 2	6/12/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

	Offenbacher et al.; Effects of NSAIDs on beagle crevicular cyclooxygenas metabolites and periodontal bone loss; J Periodont Res 1882; 27:207-213

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOC KET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

Darryl/4727C2ids.doc